OVID
Ovid Therapeutics Inc

6,126
Mkt Cap
$213.5M
Volume
1.19M
52W High
$2.01
52W Low
$0.2425
PE Ratio
-3.21
OVID Fundamentals
Price
$1.59
Prev Close
$1.64
Open
$1.66
50D MA
$1.63
Beta
1.18
Avg. Volume
1.62M
EPS (Annual)
-$0.3728
P/B
2.61
Rev/Employee
$24,608.70
$27.88
Loading...
Loading...
News
all
press releases
Ovid Therapeutics $OVID Position Cut by TLS Advisors LLC
TLS Advisors LLC lowered its holdings in shares of Ovid Therapeutics (NASDAQ:OVID - Free Report) by 97.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and...
MarketBeat·11d ago
News Placeholder
More News
News Placeholder
Ovid Therapeutics (NASDAQ:OVID) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen lowered Ovid Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·26d ago
News Placeholder
Wall Street Zen Upgrades Ovid Therapeutics (NASDAQ:OVID) to "Hold"
Wall Street Zen upgraded Ovid Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·2mo ago
News Placeholder
FY2025 Earnings Forecast for OVID Issued By Lifesci Capital
Ovid Therapeutics (NASDAQ:OVID - Free Report) - Equities researchers at Lifesci Capital issued their FY2025 earnings estimates for Ovid Therapeutics in a research report issued on Monday, December...
MarketBeat·2mo ago
News Placeholder
Ovid Therapeutics (NASDAQ:OVID) Earns Outperform Rating from Analysts at Lifesci Capital
Lifesci Capital assumed coverage on shares of Ovid Therapeutics in a research report on Monday. They set an "outperform" rating and a $4.00 price objective for the company...
MarketBeat·2mo ago
News Placeholder
Ovid Therapeutics' (OVID) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright restated a "buy" rating and issued a $2.00 price objective on shares of Ovid Therapeutics in a research report on Monday...
MarketBeat·2mo ago
News Placeholder
Ovid Therapeutics (NASDAQ:OVID) Upgraded at Roth Capital
Roth Capital raised shares of Ovid Therapeutics to a "strong-buy" rating in a research note on Thursday...
MarketBeat·2mo ago
News Placeholder
Ovid Therapeutics Names Petra Kaufmann Chief Medical Officer
(RTTNews) - Ovid Therapeutics Inc. (OVID) on Tuesday announced the appointment of Petra Kaufmann as its chief medical officer...
Nasdaq News: Markets·2mo ago
News Placeholder
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from Analysts
Shares of Ovid Therapeutics (NASDAQ:OVID - Get Free Report) have been given a consensus rating of "Buy" by the nine analysts that are presently covering the stock, Marketbeat reports. One analyst has...
MarketBeat·3mo ago
News Placeholder
William Blair Issues Pessimistic Forecast for OVID Earnings
Ovid Therapeutics (NASDAQ:OVID - Free Report) - Stock analysts at William Blair cut their FY2025 EPS estimates for Ovid Therapeutics in a research note issued to investors on Wednesday, November...
MarketBeat·3mo ago
<
1
2
...
>

Latest OVID News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.